Combining humanized mice, neurochemical, imaging, and cognitive biomarkers for drug discovery in mice.

We aim to establish a robust cost-effective pipeline that improves the translation of preclinical discoveries to clinical success, ultimately accelerating the development of effective treatments for synucleinopathies and reducing the risk of late-stage drug failures.